`
`
`
`UNITED STATES PATENT AND TRADEMARK OFFICE
`______________
`
`BEFORE THE PATENT TRIAL AND APPEAL BOARD
`______________
`
`
`
`TEVA PHARMACEUTICALS USA, INC.,
`Petitioner,
`
`v.
`
`INDIVIOR UK LIMITED,
`Patent Owner.
`______________
`
`
`
`Case IPR2016-00280
`Patent 8,475,832
`______________
`
`
`PETITIONER’S SECOND UPDATED MANDATORY NOTICES
`
`
`
`
`
`Teva Pharmaceuticals USA, Inc. (“Petitioner”) hereby updates its
`
`Mandatory Notices to inform the Board of a change in status in a Related
`
`Proceeding. Accordingly, pursuant to 37 C.F.R. § 42.8, Petitioner hereby provides
`
`the following updated Mandatory Notices.
`
`I.
`
`37 C.F.R. § 42.8(b)(1) – REAL PARTY-IN-INTEREST
`(UNCHANGED)
`
`The real party-in-interest is Teva Pharmaceuticals USA, Inc., (“Teva” or
`
`“Petitioner”)1.
`
`II.
`
`37 C.F. R. § 42.8(b)(2) – RELATED PROCEEDINGS (REVISED)
`
`The following proceedings may affect or be affected by a decision in this
`
`proceeding:
`
`Name
`
`Number
`
`District
`
`Indivior Inc. et al v. Sandoz Inc.
`
`1-15-cv-01051
`
`DED
`
`Indivior Inc. et al v. Mylan Technologies Inc.
`
`1-15-cv-00209
`
`WVND
`
`et al
`
`
`1 Teva is an indirect, wholly-owned subsidiary of Teva Pharmaceutical Industries
`
`Ltd. Teva is owned by 1) Orvet UK, which in turn is owned by Teva
`
`Pharmaceuticals Europe B.V., which in turn is owned by Teva Pharmaceutical
`
`Industries Ltd. and 2) Teva Pharmaceutical Holdings Cooperative U.A., which in
`
`turn is owned by IVAX LLC, which is owned by Teva Pharmaceuticals USA, Inc.
`
`
`
`
`2
`
`
`
`
`
`Indivior Inc. et al v. Mylan Technologies Inc.
`
`1-15-cv-01016
`
`DED
`
`et al
`
`Reckitt Benckiser Pharmaceuticals Inc. et al
`
`1-15-cv-00477
`
`DED
`
`v. Alvogen Pine Brook, Inc.
`
`Reckitt Benckiser Pharmaceuticals Inc. et al.
`
`1-14-cv-01451
`
`DED
`
`v. Teva Pharmaceuticals USA, Inc.
`
`Reckitt Benckiser Pharmaceuticals Inc. et al
`
`1-14-cv-00422
`
`DED
`
`v. Par Pharmaceutical, Inc. et al
`
`Reckitt Benckiser Pharmaceuticals Inc. et al
`
`1-13-cv-02003
`
`DED
`
`v. Alvogen Pine Brook Inc.
`
`Reckitt Benckiser Pharmaceuticals Inc. et al
`
`1-13-cv-01674
`
`DED
`
`v. Watson Laboratories Inc., et al.
`
`Reckitt Benckiser Pharmaceuticals, Inc. et al
`
`1-13-cv-01461
`
`DED
`
`v. Par Pharmaceutical, Inc. et al
`
`
`
`
`
`
`
`
`
`On June 3, 2006, the District Court for the District of Delaware in Reckitt
`
`Benckiser Pharmaceuticals Inc., et al v. Par Pharmaceutical, Inc., et al, 1-14-
`
`cv-00422, and Reckitt Benckiser Pharmaceuticals Inc. et al v. Watson
`
`Laboratories Inc., et al., 1-13-01674, found that claims 1, 3, 6, and 15-19 of the
`
`
`
`
`3
`
`
`
`
`
`’832 patent are invalid as obvious over the prior art. The decision is filed on the
`
`docket for case 13-cv-01674.
`
`
`
`The following administrative proceedings may affect or be affected by a
`
`decision in this proceeding:
`
`
`
`Petitioner is aware of at least one currently-pending U.S. patent
`
`application that claims the benefit of the ’514 Patent: U.S. Patent Application
`
`Serial No. 14/572,173 filed on December 16, 2014, which is pending.
`
`III. 37 C.F.R. § 42.8(b)(3) - LEAD AND BACKUP COUNSEL
`(UNCHANGED)
`
`
`Lead Counsel
`
`Backup Counsel
`
`Elizabeth Holland
`(Reg. No. 47, 657)
`GOODWIN PROCTER LLP
`The New York Times Building
`620 Eight Avenue
`New York, NY 10018
`Tel.: (212) 813-8800
`Fax: (212) 355-3333
`eholland @goodwinprocter.com
`
`
`Jennifer A. Albert
`(Reg. No. 32,012)
`Eleanor M. Yost
`(Reg. No. 58,013)
`J. Coy Stull
`(Reg. No. 62,599)
`GOODWIN PROCTER LLP
`901 New York Avenue NW
`Washington, DC 20001
`Tel.: (202) 346-4000
`Fax: (202) 346-4444
`JAlbert@goodwinprocter.com
`eyost@goodwinprocter.com
`jstull@goodwinprocter.com
`
`Elaine H. Blais
`Robert Frederickson III
`(both to seek pro hac vice admission)
`GOODWIN PROCTER LLP
`Exchange Place
`53 State Street
`
`
`
`
`4
`
`
`
`
`
`
`
`Boston, Massachusetts 02109
`Tel.: (617) 570-1000
`Fax: (617) 523-1231
`eblais@goodwinprocter.com
`rfrederickson@goodwinprocter.com
`
`Robert V. Cerwinski
`(to seek pro hac vice admission)
`GOODWIN PROCTER LLP
`The New York Times Building
`620 Eighth Avenue
`New York, NY 10018
`Tel.: (212) 813-8800
`Fax: (212) 355-3333
`rcerwinski@goodwinprocter.com
`
`IV. 37 C.F.R. § 42.8(b)(4) - SERVICE INFORMATION (UNCHANGED)
`
`Please direct all correspondence to counsel at the contact information above.
`
`Petitioner consents to service by electronic mail.
`
`
`
`Dated: June 7, 2016
`
`Respectfully submitted,
`
`/Elizabeth J. Holland/
`Elizabeth J. Holland
`(Reg. No. 47,657)
`Counsel for Petitioner Teva Pharmaceuticals
`USA, Inc.
`
`
`
`
`
`
`
`
`
`
`5
`
`
`
`
`
`CERTIFICATE OF SERVICE
`
`The undersigned hereby certifies that the foregoing: PETITIONER’S
`
`SECOND UPDATED MANDATORY NOTICES was served electronically via
`
`e-mail on June 7, 2016 on the following:
`
`Andrea G. Reister
`
`areister@cov.com
`
`Enrique D. Longton
`
`rlongton@cov.com
`
`Dustin B. Weeks
`
`dustin.weeks@troutmansanders.com
`
`By: /Sarah Fink /
` Sarah Fink
`
`Dated: June 7, 2016
`
`
`
`
`
`
`
`6